ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Assessment of Letermovir as Universal Prophylaxis for Cytomegalovirus Infection in Lung Transplant Recipients

L. F. Borges, T. Sparkman, K. Gutierrez, J. Banbury

UAB Hospital, Birmingham, AL

Meeting: 2022 American Transplant Congress

Abstract number: 1472

Keywords: Cytomeglovirus, Lung, Lung transplantation, Prophylaxis

Topic: Clinical Science » Lung » 64 - Lung: All Topics

Session Information

Session Name: Lung Transplantation

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Cytomegalovirus (CMV) poses a significant concern in the post-operative management of lung transplant (LT) recipients. Current recommended prophylactic strategies with ganciclovir (GCV) or valganciclovir (VGC) can be complicated by myelosuppressive adverse effects. Letermovir may be utilized as an alternative agent for CMV prophylaxis, although clinical data is limited in LT. The purpose of this study is to compare the incidence of breakthrough CMV viremia between letermovir and VGC/GCV at our institution.

*Methods: This single-center, retrospective study included all recipients of LT at our institution from January 1, 2016 to September 30, 2021. The primary outcome was incidence of breakthrough CMV viremia defined as any detectable viral load while on universal prophylaxis. Secondary outcomes included adjustments to maintenance immunosuppression, development of donor-specific antibodies (DSA), and biopsy proven acute rejection (BPAR).

*Results: A total of 34 LT recipients were included and received CMV prophylaxis with letermovir (n=8) or VGC/GCV (n=26). Standard immunosuppressive therapy included basiliximab induction and triple maintenance immunosuppression. The primary indication for transitioning prophylaxis to letermovir was leukopenia or thrombocytopenia. Median time from LT to letermovir initiation was 100.5 days (range: 82-499 days). A detectable viral load developed in four (50%) letermovir patients and five (19%) VGC/GCV patients. No patient required treatment for CMV disease after transitioning to letermovir. Eight patients receiving letermovir previously required suspension of their antimetabolite; four of these patients were successfully re-challenged. Development of DSA occurred in three (38%) letermovir patients and four (15%) VGC/GCV patients. Incidence of BPAR was similar between groups. Data collection and statistical analysis are ongoing.

*Conclusions: At our institution, universal prophylaxis with letermovir was associated with a higher incidence of low-level viremia compared to standard prophylaxis, however, no letermovir patients required escalation for CMV treatment. An antimetabolite was successfully reinitiated in a proportion of patients previously requiring antimetabolite cessation prior to letermovir initiation. Preliminary results indicate a comparable incidence of rejection at 6 months post-transplant.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Borges LF, Sparkman T, Gutierrez K, Banbury J. Assessment of Letermovir as Universal Prophylaxis for Cytomegalovirus Infection in Lung Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/assessment-of-letermovir-as-universal-prophylaxis-for-cytomegalovirus-infection-in-lung-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences